Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: Association with the activity of pulmonary fibrosis

Clinical and Experimental Rheumatology

Volumn 21, Issue 4, 2003, Pages 429-436

  Yanaba, K ^a,b   Hasegawa, M ^a   Hamaguchi, Y ^a   Fujimoto, M ^c   Takehara, K ^a   Sato, Shinichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Disease activity; KL 6; Longitudinal study; Pulmonary fibrosis; Systemic sclerosis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLYCOPROTEIN; IMMUNOSUPPRESSIVE AGENT; KL 6 ANTIGEN; MONOCLONAL ANTIBODY; PENICILLAMINE; PREDNISOLONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS;

ADULT; ANALYSIS OF VARIANCE; ANTIGENS; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUCINS; PROBABILITY; PROGNOSIS; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0043201220     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. SILVER RM: Clinical problems: the lungs. Rheum Dis Clin North Am 1996; 22: 825-840.
2. STEEN VD, CONTE C, OWENS GR, MEDSGER TA: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-9.
3. KOHNO N, AKIYAMA M, KYOIZUMI S, HAKODA M, KOBUKE K, YAMAKIDO M: Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988; 18: 203-16.
4. KOHNO N, KYOIZUMI S, AWAYA Y, FUKUHARA H, YAMAKIDO M, AKIYAMA M: New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest 1989;96:68-73.
5. KOBAYASHI J, KITAMURA S: KL-6: A serum marker for interstitial pneumonia. Chest 1995; 108: 311-5.
6. HAMADA H, KOHNO N, AKIYAMA M, HIWADA K: Monitoring of serum KL-6 antigen in a patients with radiation pneumonia. Chest 1992; 101: 858-60.
7. KOBAYASHI J, KITAMURA S: Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest 1996; 109: 1276-82.
8. NAKAJIMA H, HARIGAI M, HARA M, et al.: KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol 2000;27:1164-70.
9. YAMANE K, IHN H, KUBO M, YAZAWA N, KIKUCHI K, SOMA Y, et al.: Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol 2000;27:930-4.
10. SATO S, NAGAOKA T, HASEGAWA M, NISHIJIMA C, TAKEHARA K: Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 2000; 200: 196-201.
11. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
12. LeROY EC, KRIEG T, BLACK C, et al.: Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5.
13. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
14. CLEMENTS PJ, LACHENBRUCH PA, SEIBOLD JR et al.: Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20:1892-6.
15. SATO S, HAMAGUCHI Y, HASEGAWA M, TAKEHARA K: Clinical significance of antitopoisomerase I antibody levels by ELISA in systemic sclerosis. Rheumatology 2001;40: 1135-40.
16. KAZEROONI EA, MARTINEZ FJ, FLINT A et al.: Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997;169:977-83.
17. KOBAYASHI J, ITOH Y, KITAMURA S, KAWAI T: Establishment of reference intervals and cut-off value by an enzyme immunoassay for KL-6 antigen, a new marker for interstitial pneumonia. Jpn J Clin Pathol 1996; 44: 653-8.
18. KOHNO N, AWAYA Y, OYAMA T et al.: KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993; 148:637-42.
19. ROSSI GA, BITTERMAN PB, RENNARD SI, FERRANS VJ, CRYSTAL RG: Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Respir Dis 1985;131:612-7.
20. DINES DE: Pulmonary disease of vascular origin. Dis Chest 1968;54:3-12.
21. SILVER RM, WARRICK JH, KINSELLA MB, STAUDT LS, BAUMANN MH, STRANGE C: Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20:838-44.
22. STEEN VD, LANZ JK, JR, CONTE C, OWENS GR, MEDSGER TA, Jr: Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37: 1290-6.
23. PAKAS I, IOANNIDIS JP, MALAGARI K, SKOPOULI FN, MOUTSOPOULOS HM, VLACHOYIANNOPOULOS PG: Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29: 298-304.
24. WHITE B, MOORE WC, WIGLEY FM, XIAO HQ, WISE RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
25. IMOKAWA S, SATO A, HAYAKAWA H, KOTANI M, URANO T, TAKADA A: Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156: 631-6.